Larkspur Biosciences develops precision cancer immunotherapies using its proprietary LarkX platform, which leverages patient genetics, immune phenotypes, bioinformatics, and complex in vitro models to discover immune-evasion signatures. Its lead programs include an approach to lipid remodeling intended to uncloak tumors and a program targeting Pin1, a mechanism of fibroblast differentiation to activate immune cells. The company’s initial clinical strategy targets a genetically- and immunologically-characterized subtype of colorectal cancer whose patients have T cells at the tumor and can be identified via biopsy. Larkspur positions these insights as applicable across multiple cancer indications that share evasion signatures. The company is led by CEO Catherine Sabatos-Peyton and was founded by Drs. Lewis Cantley, Nathanael Gray, and Vijay K. Kuchroo. It raised financing to advance IND-enabling studies and further ongoing preclinical work.

Total raised

$36M

Funding rounds

1

Latest round

Equity

Latest activity

May 2023